World records and fight against breast cancer fundraiser
September 01, 2015
Dabigatran etexilate provides effective, predictable and consistent anticoagulation with a low potential for drug interactions and no known food interactions, without the need for routine coagulation monitoring or dose adjustment. In contrast to VKAs, which variably act via different coagulation factors, direct thrombin inhibitors achieve potent anthrombotic effects by specifically blocking the activity of thrombin (both free and clot-bound), the central enzyme in the process responsible for clot (thrombus) formation.
Earlier this year, the RE-LY(R) study (18,113 patients in 44 countries worldwide) showed groundbreaking results for dabigatran etexilate convincingly beating warfarin in stroke prevention in atrial fibrillation.
As such, dabigatran etexilate has the protential to benefit even more patients and replace warfarin as the treatment of choice.
In total, four trials involving 8,900 patients are exploring dabigatran etexilate in VTE treatment: RE-COVER(TM) and RE-COVER(TM) II in acute VTE and RE-MEDY(TM) and RE-SONATE(TM) in prevention of secondary VTE. The results of RE-COVER(TM) and the very favourable results of RE-LY add to the growing database of evidence supporting the efficacy and safety of dabigatran etexilate across a wide range of acute and chronic thromboembolic disorders from the RE-VOLUTION(R) clinical development program involving over 38,000 patients.
Source: BOEHRINGER INGELHEIM